09:27 AM EDT, 03/19/2026 (MT Newswires) -- Viatris ( VTRS ) said Thursday it projects a compound annual growth rate for total revenue of 5% to 6% through 2030.

The pharmaceutical firm's long-term financial goals also include an adjusted earnings per share compound annual growth rate between 9% and 10%, alongside over $3 billion in annual free cash flow by the end of the decade, it said.

A recent strategic review outlined roughly $650 million in gross cost reductions across a three-year span, while the company anticipates generating more than $11 billion in available capital for allocation through 2030, Viatris ( VTRS ) said.

The company also said it plans to launch Meloxicam in the US, and Pitolisant and Effexor in Japan in the near term.